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Abstract
Background—Patients with prior invasive fungal infection (IFI) increasingly proceed to 
allogeneic hematopoietic cell transplantation (HSCT), however, little is known about the impact of 
prior IFI on survival.
Methods—Patients with pre-transplant IFI (cases; n=825) were compared to controls (n=10,247). 
A subset analysis assessed outcomes in leukemia patients pre- and post-2001.
Results—Cases were older with lower performance status (KPS), more advanced disease, higher 
likelihood of acute myeloid leukemia (AML), and having received cord blood, reduced intensity 
conditioning (RIC), mold-active fungal prophylaxis and more recently transplanted. Aspergillus 
spp. and Candida spp. were the most commonly identified pathogens. 68% of patients had 
primarily pulmonary involvement. Univariate and multivariable analysis demonstrated inferior 
progression-free (PFS) and overall (OS) survival for cases. At 2 years, cases had higher mortality 
and shorter PFS with significant increases in non-relapse mortality (NRM) but no difference in 
relapse. One year probability of post-HSCT IFI was 24% (cases) and 17% (control, p <0.001). The 
predominant cause of death was underlying malignancy; infectious death was higher in cases (13 
vs 9%). In the subset analysis, patients transplanted before 2001 had increased NRM with inferior 
OS and PFS compared to later cases.
Conclusions—Pre-transplant IFI is associated with lower PFS and OS after allogeneic HSCT 
but significant survivorship was observed. Consequently, pre-transplant IFI should not be a 
contraindication to allogeneic HSCT in otherwise suitable candidates.
Introduction
Invasive fungal infections (IFI) historically portend a poor prognosis in patients undergoing 
allogeneic hematopoietic stem cell transplantation (HSCT). An observational study of the 
Transplant Associated Infection Surveillance Network (TRANSNET) suggests that post-
HSCT IFI remains problematic, with cumulative incidence rates varying between 5.8–7.7% 
in the allogeneic transplant setting1. Historically, prior mold infection was considered a 
relative contraindication to transplantation. Although the risk of reactivation of fungal 
infection in the setting of HSCT is high, HSCT may be the only remaining treatment option 
in the face of an otherwise fatal hematologic malignancy. With the advent of novel broader 
spectrum antifungal agents, prophylaxis and treatment of fungal infections have significantly 
improved. Likewise, use of granulocyte colony-stimulating growth factors has decreased the 
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length of neutropenia, a major risk factor for IFI2– 7. Additionally, reduced intensity 
conditioning (RIC) transplantation may help to minimize opportunistic infections and to 
maximize graft-versus-tumor effects8, 9. These advances in HSCT and its associated 
supportive care have enabled patients to successfully receive a HSCT despite having 
previously documented fungal infection8, 10–12
To date, there are limited data from large multicenter cohorts comparing outcomes in 
patients who have undergone allogeneic HSCT with known prior yeast or mold infection to a 
matched cohort without previous IFI. Fukuda et al. reported the outcomes of 45 patients with 
pre-transplant invasive aspergillosis (IA) treated in the pre-mold active azole era and 
demonstrated that post-transplant recurrent IA was seen in 29% and that the cases had lower 
overall survival than controls. Notably, those patients with >1 month of antifungal therapy, 
received RIC or those that had resolution of radiographic disease findings had better 
outcomes11. Martino et al. reported a retrospective survey of 129 patients with a history of 
proven or probable IA of whom 44% had undergone RIC12. They observed a 22% post-
transplant progression rate for IA at 2 years, which occurred more frequently in those 
patients undergoing conventional myeloablative HSCT, for patients with grade II–IV acute 
graft versus host disease (GVHD), for patients receiving bone marrow or cord blood 
allografts, and for patients with CMV disease. Most recently, a report from the EBMT 
analyzed the long term outcomes of pre-existing IA on transplant outcomes of patients with 
acute leukemia only13. Data were available from 1152 pts with a median follow-up of 52 
months. There was no significant impact of the pre-existing IA on overall survival, relapse 
free survival, non-relapse mortality, acute or chronic GVHD, although there was a trend 
toward lower overall survival and higher non-relapse mortality13. Herein, we explore the 
CIBMTR data base on the influence of participating center documented preexisting IFI on 
clinical outcomes after HSCT and the risk factors associated with fungal disease progression 
post-transplant. We also examine the impact of changes in supportive care over the past 
decade versus earlier time periods to determine if the evolution of conditioning regimen and 
advances in supportive care translate into improved clinical outcomes in patients with pre-
existing IFI undergoing HSCT.
Materials and Methods
Data Source and Patients
Data were obtained from the Center for International Blood and Marrow Transplant 
Research (CIBMTR). The CIBMTR is a research affiliate of the International Bone Marrow 
Transplant Registry, Autologous Blood and Marrow Transplant Registry, and the National 
Marrow Donor Program (NMDP) established in 2004. It comprises a voluntary working 
group of more than 500 transplantation centers worldwide that contribute data on 
consecutive allogeneic and autologous HCT procedures to a statistical center at the Medical 
College of Wisconsin in Milwaukee and the NMDP Coordinating Center in Minneapolis, 
Minnesota. Participating centers report longitudinal data on all transplants and compliance is 
monitored by on-site audits. Observational studies conducted by the CIBMTR are performed 
in compliance with all applicable federal regulations pertaining to the protection of human 
research participants. Protected health information used in the performance of such research 
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is collected and maintained in CIBMTR’s capacity as a Public Health Authority under the 
Health Insurance Portability and Accountability Act Privacy Rule. Studies conducted by the 
CIBMTR are performed under guidance and review of the Institutional Review Board of the 
National Marrow Donor Program. Transplant essential data, collected for consented patients 
participating in CIBMTR data collection, include demographic, disease type and stage, 
survival, relapse, graft type, the presence of GVHD, and cause of death data. A subset of 
CIBMTR participants are selected for comprehensive research level data collection by 
weighted randomization.
Subject Eligibility
The primary analysis includes all adult and pediatric patients receiving a first allogeneic 
HSCT for acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), chronic 
myeloid leukemia (CML), or myelodysplasia (MDS) between 2001 and 2009. Patients with 
severe aplastic anemia or lymphoma were excluded, recognizing the difference in natural 
history. The secondary analysis includes only patients with AML or ALL receiving a first 
allogeneic transplant following myeloablative conditioning between 1995 and 2009, 
comparing outcomes pre- and post-2001 due to improvements in supportive care and as a 
surrogate for emergence of novel antifungal agents with recognition that FDA approval for 
caspofungin and voriconazole was 2001 & 2002, respectively.
Cases—Patients reported to the CIBMTR as having a documented or suspected IFI in the 
12 months prior to allogeneic transplantation were considered as cases14–16. This 
information is reported as an event but diagnostic criteria used to determine IFI are not 
captured. Data on the organism, if available, and the site of infection are reported by the 
transplant center. Patients for whom CIBMTR forms indicated the site of infection was oral 
cavity or genitalia only were excluded from analysis, recognizing that these situations likely 
represented mucosal disease or colonization rather than true infection. Patients with an IFI 
reported more than 12 months prior to transplant were excluded.
Controls—All patients reported as “No” IFI in the 12 months prior to transplant and who 
were transplanted at the same centers were considered as contemporary controls. Any 
patients without any response (missing data) to the question of pre-transplant IFI were 
excluded. This approach was instituted to provide balance regarding selection criteria for 
HSCT as well as minimize ascertainment bias of documented/suspected IFI rather than draw 
controls from centers that may have different selection criteria and thus present an 
unintended bias toward better risk patients.
Endpoints
Non-relapse mortality (NRM) was the primary outcome. Secondary outcomes included 
relapse, progression-free survival (PFS), overall survival (OS), acute GVHD, and chronic 
GVHD. Each outcome was analyzed in both the primary and secondary analysis. NRM was 
defined as death within the first 28 days of transplant for any cause or death without relapse 
or progression of the primary malignancy. NRM was assessed at Day 100, 1 year and 2 years 
after HSCT. Relapse was defined as the recurrence of malignancy from a remission state. OS 
was determined from the date of HSCT to the time of death or last follow-up. Death was 
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considered a competing risk for assessment of cumulative incidence of relapse, acute and 
chronic GVHD. For PFS, patients were considered treatment failures at the time of relapse 
of underlying malignancy or death from any cause.
Statistical Analysis
Patient-, disease- and transplant-related factors were compared between groups using the 
Chi-square test for categorical variables and the Wilcoxon test for continuous variables. The 
probabilities of PFS and OS were calculated using the Kaplan-Meier estimator. Probability 
estimates for other endpoints were generated using cumulative incidence functions to 
account for competing risks.
Multivariable analyses for outcomes at 2 years were performed using pseudo-value approach 
to adjust for other potentially significant covariates and determine if there is an interaction 
with the main effect variable of the presence or absence of a pre-transplant IFI 17, 18. Other 
risk factors include age, CMV serostatus, disease, disease stage, conditioning intensity, graft 
type, degree of HLA match, GVHD prophylaxis, peri-transplant T cell depletion and post-
transplant use of growth factor. Interaction between the main effect and significant 
covariates were tested and reported to assess for differences between cases and controls. 
Multivariable models were built using a backward variable selection method. All P-values 
are 2-sided, the level of significance (alpha) of 0.05 was used throughout. All analyses were 
carried out using SAS Version 9.3 statistical software (SAS Institute, Cary, NC).
Results
Patient Characteristics
Patient, disease and transplant characteristics are presented in Table 1 for the primary 
analysis of the 825 patients with reported prior IFI transplanted between 2001 and 2009 and 
the 10,247 controls transplanted at the same center without reported prior IFI. The fungal 
pathogens that were identified as IFI included 199 Candida spp. infections, 281 Aspergillus 
spp. infections, and 50 “other” fungal infections, including Mucormycosis, Fusarium and 
Cryptococcus. Infections reported as “suspected” were identified in 295 patients and are 
included. Five hundred fifty-seven (68%) patients had pulmonary infections while 261 
(32%) had only extra-pulmonary involvement. The median time from infection to transplant 
was approximately 3.5 months (range <1–12 months); thus, more than 50% of the patients 
experienced their IFI more than 100 days prior to HSCT. For both cases and controls, the 
time from diagnosis of hematologic malignancy to transplant were 7 (<1 – 310) and 8 (<1 – 
607) months (p=0.277), respectively. Details of the status of the IFI at time of transplant 
were not available in the CIBMTR database. As expected, significant differences between 
the cases and the controls existed. Cases were older, more likely to have compromised 
performance status and more advanced acute leukemia, and to have received mold active 
secondary fungal prophylaxis. Cases were more likely to receive cord blood as a stem cell 
source, to receive reduced intensity/non-myeloablative conditioning regimens and 
transplants in more recent years, and to receive non-methotrexate-containing GVHD 
prophylaxis regimens19. No significant differences were found in donor/recipient CMV 
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status, gender, use of growth factor support, and use of steroid-containing GVHD 
prophylaxis between the case and control cohorts.
Survival, Non-relapse Mortality and Relapse Outcomes
Univariate probabilities of outcomes of interest after HSCT between subjects with pre-
existing IFI and those without IFI are summarized in Table 2. In nearly all outcomes 
measured, statistical differences between the cases and the controls at 1, 3, and 5 years after 
HSCT were noted. There were no differences in univariate transplant outcomes for OS, 
TRM, DFS, RR, aGVHD or cGVHD (data not shown) when comparing Aspergillus spp. 
cases, Candida spp. cases, Other fungal cases, and Suspected IFI so all pre-transplant IFIs 
were combined for the univariate analysis. OS was 30% (95% Confidence interval (CI): 26 – 
34%) at 5 years in patients with pre-transplant IFI versus 45% (95% CI: 44 – 46%) in the 
control population (p < 0.0001) (Figure 1). The lower OS was a composite reflection of 
higher relapse rates and higher NRM in the cases. Interestingly, acute GVHD by 100 days 
and chronic GVHD at 1, 3, and 5 years were statistically less frequent in the patients with 
reported pre-existing IFI (aGVHD: cases 34%, controls 39%, p=0.0022; cGVHD at 5 years: 
cases 36%, controls 45%, p <0.0001) (Table 2). Additionally, reported post-transplant IFI 
occurred more commonly in the cases versus controls at 3 months, 6 months, and 1 year 
after HSCT. Only 144 (17%) patients with pre-HSCT IFI were subsequently reported as 
developing a post-transplant IFI; of these, 46 (32%) experienced relapse with the previously 
identified fungal pathogen, while 97 (67%) patients had fungal pathogens different from the 
original pathogen reported. One patient had an unidentified fungus reported.
As shown in Table 3, on multivariable analysis, cases with pre-transplant IFI had higher 
overall mortality [Relative Risk {RR} 1.33, 95%CI (1.19 – 1.48), p <0.0001] and shorter 
PFS at 2 years [RR of relapse or death 1.24, 95%CI (1.11 – 1.38), p <0.0001] with 
significant increases in NRM [RR 1.27 (1.09 – 1.49), p = 0.002] compared to the control 
cohort (Figure 2). Relapse rates were not significantly increased [RR=1.04, 95%CI (0.91 – 
1.18), p = 0.58]. The risk of being diagnosed with aGVHD by day 100 was similar between 
the cases and controls [RR 0.9, 95%CI (0.80 – 1.02), p = 0.09] with lower risk of cGVHD 
[RR 0.81, 95%CI (0.71 – 0.93), p = 0.002] identified in the cases. Additionally, when 
comparing cases with the control patients at one year, there was a greater likelihood of 
experiencing a post-transplant IFI [RR 1.36, 95%CI (1.16 – 1.58), p = 0.001].
Other factors negatively impacting OS and PFS include older age by decade, receipt of ATG 
or alemtuzumab, recipient CMV serostatus positive regardless of donor CMV serostatus, 
AML or ALL, more advanced disease, receiving cord blood or other related donor, and 
performance status <90%. OS, but not PFS, was decreased in patients receiving less than a 
well matched unrelated donor. PFS but not OS was improved if the patient received 
myeloablative conditioning. Non-relapse mortality was increased in older patients, ALL, 
CML, intermediate but not advanced disease status, use of either alternative related, 
mismatched unrelated, or cord blood as the stem cells source, and lower performance status. 
At 2 years, the NRM was significantly better for patients receiving RIC/NMA conditioning. 
Finally, the use of ATG or alemtuzumab, advanced disease stage, and RIC/NMA 
conditioning increased the relative risk of relapse.
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The relative risk for a fungal infection of any kind at 1 year post transplant was enhanced by 
the presence of pre-transplant IFI compared with controls [RR 1.35, 95%CI (1.16 – 1.58)]. 
Other risk factors associated with increased risk of fungal infection at 1 year post-transplant 
include older age, receipt of alemtuzumab [RR 1.51, 95%CI (1.24 – 1.85)] or ATG exposure 
[RR 1.16, 95%CI (1.04 – 1.29], advanced malignancy [RR 1.45, 95%CI (1.29–1.63)] and 
cord blood [RR 1.48, 95%CI (1.24 – 1.75)] or mismatched related donor [RR 1.43, 95%CI 
(1.13 – 1.79)). For the cases, there was no impact on OS, PFS, NRM, and GVHD based on 
the type of pre-transplant IFI, whether yeast or mold (data not shown).
Cause of Death
There were no differences between cause of death between patients with pre-transplant IFI’s 
and controls (see Table 4). Recurrent disease was the most likely cause of death in both 
cohorts. Organ failure, GVHD, and infections comprised the majority of other etiologies, 
with rare events including graft failure, secondary malignancy, bleeding, and idiopathic 
pneumonitis syndrome.
Secondary analysis
A secondary analysis was performed to determine the influence of era of diagnosis of IFI, 
acknowledging the impact of advances in antifungal therapy and supportive care in more 
recent years. This analysis was restricted to patients receiving myeloablative allogeneic 
transplantation for acute myeloid or lymphoid leukemia, and reflected the interval between 
1995 and 2009 (suppl Table 1).
For subjects with pre-transplant IFI, the median age was lower in the earlier compared to the 
later time period, but again patients were more likely to have advanced disease and myeloid 
leukemia. Amphotericin products were most commonly used as the antifungal prophylaxis 
agent of choice, either solely or in conjunction with other agents, in the earlier years. No 
differences were seen in GVHD prophylaxis regimens containing steroids, ATG or 
alemtuzumab.
Similar to observations made from the primary analysis, within the secondary analysis, 
univariate and adjusted probabilities for overall mortality, NRM, and IFI developing within 
one year post-transplant were higher for patients with pre-transplant IFI versus the control 
cohort. PFS was also worse among patients with diagnosed pre-HSCT IFI. Interestingly, 
when outcomes of study subjects with pre-transplant IFI within the time frame 1995–2000 
were compared to a more recent patient population who underwent myeloablative 
conditioning for AML and ALL performed between 2001 and 2009, improved OS (Figure 3) 
was noted in the modern era, which appear attributable to decreases in NRM (Figure 4).
Discussion
This retrospective CIBMTR analysis is performed on a large cohort of transplant patients 
reported to have documented or suspected pre-transplant IFI. The vast majority of these IFI 
were a consequence of infections with Candida spp. and Aspergillus spp., although other 
fungal infections were represented, including Fusarium and Mucormycosis. A similar 
analysis has recently been reported by the EBMT of a cohort of HSCT patients with acute 
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leukemia, transplanted between 2005 and 2010, specifically with preexisting invasive 
Aspergillus spp. (IA) infections. Their analysis identified that excellent outcomes can be 
achieved despite the preexisting IA. Our data substantiate these observations13. Historically, 
before the emergence of mold-active echinocandins and azoles, many centers would not 
consider HSCT in patients with pre-existing IFI, particularly for those patients with 
antecedent mold infections. This current study demonstrates that positive outcomes can be 
obtained in these patients and that suspected or documented pre-transplant IFI by 
themselves, whether they are IA, candida or other identified mycoses, should not preclude 
patients from pursuing potentially curative transplant procedures for underlying malignant 
disease. Lower PFS and OS are seen in these patients; however, this augmented mortality 
was not due to the identified higher rates of recurrent fungal infection, but rather, influenced 
by disease status. This finding is not unexpected, as patients with fungal infections would be 
predicted to be more likely be transplanted later, to assure ample time for antifungal therapy 
to achieve response to treatment prior to transplantation (often defined by radiographic 
remissions11), to receive reduced intensity conditioning or to be electively transplanted only 
if disease is recurrent. The data reported within this analysis would suggest that delaying 
HSCT for patients with effectively treated pre-HSCT IFI may not be necessary and could 
actually contribute to worse outcomes due to disease recurrence.
The study also demonstrated that progress has been made in treating IFI with improved 
outcomes in the more modern era20. Our secondary analysis could not demonstrate any 
major change in any outcome in the amphotericin era between patients with pre-transplant 
IFI’s and those without when compared to the more recent expanded-spectrum azole/
echinocandin era. This secondary analysis was performed as a surrogate for changes in 
antifungal prophylaxis since the data reported to the CIBMTR for antifungal prophylaxis 
collects antifungal drug received but not dose, sequence of agents or length of schedule. 
Notwithstanding these limitations, as a whole, patients transplanted in more recent years 
were more likely to survive the HSCT experience 21,22. A higher risk of death for patients 
with pre-transplant IFI was noted in all years, but this has recently diminished due to a more 
global reduction in NRM. Interestingly, in the primary analysis we found that 83% (n = 681) 
of the subjects with documented or suspected pre-transplant IFI were not reported to develop 
post-transplant IFI’s. One hundred forty-three (17%) patients were diagnosed with post-
transplant IFI, similar to other reported fungal infection incidence for patients without prior 
history1. Interestingly, only one third of those patients who developed a post-transplant IFI 
actually reactivated their prior IFI, a lower incidence than reported previously 11 and actually 
could suggest that these individuals are possibly predisposed to developing IFI 23.
We do not have information about how many and which patients with pre-transplant IFI 
from the selected centers did not proceed to transplant. When one reviews the patient, 
disease and transplant variables, there are clues that indicate that these patients were indeed 
a selected population. They were more likely to have been treated with more aggressive 
antifungal prophylaxis and more likely to have been treated with reduced intensity/non-
myeloablative transplant procedures. Interestingly, in the more recent patient population, 
there were less extra pulmonary fungal infections reported prior to transplant, possibly 
suggesting that new diagnostic approaches and improvements of radiologic detection may 
have contributed to better pre-transplant fungal detection followed by early therapy 24.
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Unfortunately, we do not have documentation of the extent of the pre-transplant infection or 
the degree of infection control of the reported pre-transplant IFI. The patients who 
proceeded to transplant were more likely to have more advanced disease and lower 
performance status, but these observations might suggest that they were more deeply treated 
with chemotherapy before taking them to transplant. Additionally, it is curious to see that 
after transplant, there were lower rates of GVHD reported in the cases. There was a higher 
likelihood of utilizing RIT in the cases. One could also hypothesize that awareness of the 
pre-existing IFI influenced the treatment team to less aggressively taper calcineurin inhibitor 
immune suppression to avoid GVHD and subsequent use of high dose corticosteroid 
exposure, an approach that may not have been taken otherwise in patients with advanced 
disease. Alternatively, more frequent use of voriconazole in the cases may have led to higher 
levels of calcineurin inhibitors owing to drug-drug interactions, which may explain the lower 
rates of GVHD. Another possibility relates to recent observations that treatment of resistant 
candida has been augmented by adjunct therapy with calcineurin inhibitors 25,26. These 
hypotheses cannot be tested, as information regarding the decision-making of the transplant 
teams on management in these cases is not available, as is often the case in retrospective 
registry studies.
There are limitations to this study. Collected CIBMTR data do not provide pre-or post-
HSCT detailed antifungal prophylaxis schedules. We are limited by the data included within 
the CIBMTR forms; we do not have information regarding dose, duration, possible sequence 
of treatment nor do we have availability of drug levels. There are ongoing updates of the 
data collection forms, but the forms’ evolution will not impact the data previously collected. 
Additionally, there is a dearth of immune reconstitution data that accompanies these 
analyses. Also, there are variations in how centers may report “suspected” IFI. We would 
anticipate that many of the academic centers contributing data to the CIBMTR would report 
“suspected” IFI for patients with “probable” IFI as defined according to established EORTC 
or other similar guidelines27. Reporting for this study is entered within the category defined 
as “suspected” IFI within the CIBMTR data collection fields but the congruence between the 
two definitions is not confirmed. Reporting is up to the transplant leaders at the transplant 
centers. Hopefully, as more detailed tools evolve to dissect mild, moderate and severe 
infections with their impact on the host, such as defined within the Manual of Procedures of 
the Blood & Marrow Transplant Clinical Trials Network, a greater understanding will 
emerge which should positively impact the transplant recipient28, 29. Ultimately, definitive 
conclusions of the impact on pre-existing IFI can only be drawn from prospective studies, 
but with the emergence of better antifungal prophylaxis agents, the patient numbers to 
perform such studies may not be present.
Overall, 30% long-term overall survival was achieved in patients with perceived life-
threatening pre-transplant IFI and most commonly with advanced disease at time of 
transplant. Additionally, the risk of post-transplant fungal disease re-emergence was low, 
only recorded at 6% in this retrospective study. Forewarned is forearmed, and with more 
active primary or secondary fungal prophylaxis for mold and resistant Candida species, 
transplantation should remain a high priority consideration, rather than a contraindication, 
for patients with hematologic malignancies and prior IFI. However, these data still 
demonstrate that lower outcomes are seen in these patients with pre-transplant IFIs and 
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further analysis is required to determine if we can identify those factors that impact survival 
such as the presence of yeast versus mold infections, the impact of complete or partial 
radiographic resolution at the time of transplantation, and whether or not, longer-term 
utilization of post-transplant antifungal therapies could improve survival.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Key points
Documented pre-transplant IFI is associated with lower PFS and OS after allogeneic 
HSCT. However, mortality post-transplant is more influenced by advanced disease status 
than previous IFI. Pre-transplant IFI does not appear to be a contraindication to 
allogeneic HSCT
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Figure 1. 
Overall survival from the time of transplant for patients with (Cases, solid line) and without 
(Controls, dashed line) an invasive fungal infection in the 12 months prior to allogeneic 
transplantation. The point-wise comparison at 5 years is shown.
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Figure 2. 
Non-relapse mortality from the time of transplant for patients with (Cases, solid line) and 
without (Controls, dashed line) an invasive fungal infection in the 12 months prior to 
allogeneic transplantation. The point-wise comparison at 5 years is shown.
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Figure 3. 
Overall survival from the time of transplant for AML and ALL patients receiving 
myeloablative conditioning with IFI transplanted between 1995 – 2000 (solid line) and 
between 2001 – 2009 (dashed line). The point-wise comparison at 5 years is shown.
Maziarz et al. Page 16
Bone Marrow Transplant. Author manuscript; available in PMC 2017 June 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. 
Non-relapse mortality from the time of transplant for AML and ALL patients receiving 
myeloablative conditioning with IFI transplanted between 1995 – 2000 (solid line) and 
between 2001 – 2009 (dashed line). The point-wise comparison at 5 years is shown.
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Table 1
Characteristics of patients who underwent allogeneic transplants for AML, ALL, CML, MDS and had Invasive 
fungal infection within 12 months prior to transplant vs. those who had no documented invasive fungal 
infection within 12 months prior to transplant, reported to the CIBMTR, from 2001 to 2009
Variable
Pre-tx invasive fungal infection
N (%)
All others
N (%) p_value
Patient related
Number of patients 825 10247
Number of centers 158 158
Age, median(range), years (age) 44 (1 – 74) 39 (<1 – 79) <0.001
Age at transplant, years <0.001
 <=10 81 (10) 1039 (10)
 11–20 96 (12) 1313 (13)
 21–30 97 (12) 1417 (14)
 31–40 89 (11) 1495 (15)
 41–50 150 (18) 1848 (18)
 >50 312 (38) 3135 (31)
Gender 0.937
 Male 465 (56) 5761 (56)
 Female 360 (44) 4486 (44)
Lansky/Karnofsky score at transplant <0.001
 <90 282 (34) 2507 (24)
 >=90 504 (61) 7294 (71)
 Missing 39 (5) 446 (4)
Disease-related
Disease <0.001
 AML 609 (74) 5310 (52)
 ALL 171 (21) 2548 (25)
 CML 22 (3) 1578 (15)
 MDS 23 (3) 811 (8)
Disease stage at transplant <0.001
 AML/ALL/CML/MDS Early 378 (46) 5335 (52)
 AML/ALL/CML Intermediate 218 (26) 2701 (26)
 AML/ALL/CML/MDS Advanced 229 (28) 2211 (22)
Time from Infection to transplant (months)
 0–2 211 (26)
 2–6 479 (58)
 6–12 135 (16)
Time from Infection to transplant, median(range), days 105 (7 – 362)
Time from Infection to transplant
 0–29 days 49 (6)
 30–59 days 154 (19)
 60–99 days 186 (23)
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Variable
Pre-tx invasive fungal infection
N (%)
All others
N (%) p_value
 100–179 days 291 (35)
 180–365 days 145 (18)
Type of fungal infection
 Aspergillus 281 (34)
 Mucormycosis 9 (1)
 Other Mold infection 19 (2)
 Candida albicans 56 (7)
 Other Candida 143 (17)
 Suspected fungal infection 295 (36)
 Other 22 (3)
Infection Location
 Localized extrapulmonary 261 (32)
 Pulmonary 557 (68)
 Combine Pulmonary and extrapulmonary 7 (<1)
Received antifungal prophylaxis <0.001
 None 108 (13) 1555 (15)
 Amphotericin +/− others 136 (16) 885 (9)
 Fluconazole +/− others 279 (34) 5764 (56)
 Itraconazole +/− others 54 (7) 674 (7)
 Voriconazole +/− others 175 (21) 994 (10)
 Posiconazole +/− others 23 (3) 163 (2)
 Echinocandin +/− others 50 (6) 212 (2)
Transplant-related
Donor/Recipient CMV status 0.268
 +/+ 303 (37) 3652 (36)
 +/− 81 (10) 1041 (10)
 −/+ 215 (26) 2631 (26)
 −/− 187 (23) 2563 (25)
 Missing 39 (5) 360 (4)
Donor/recipient gender match 0.002
 Male-Male 289 (35) 3541 (35)
 Male-Female 195 (24) 2456 (24)
 Female-Male 150 (18) 2024 (20)
 Female-Female 133 (16) 1802 (18)
 Donor gender missing 58 (7) 424 (4)
Donor/recipient HLA match 0.003
 Cord blood 124 (15) 1196 (12)
 HLA-identical siblings 356 (43) 4340 (42)
 Other related 34 (4) 345 (3)
 Well matched unrelated 180 (22) 2722 (27)
 Partially matched unrelated 87 (11) 1149 (11)
 Mismatched unrelated 19 (2) 290 (3)
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Variable
Pre-tx invasive fungal infection
N (%)
All others
N (%) p_value
 Unrelated (HLA match information missing) 25 (3) 205 (2)
GVHD prophylaxis <0.001
 t-cell depletion 47 (6) 601 (6)
 FK506+MTX +/− other 222 (27) 2969 (29)
 FK506 +/− other 98 (12) 1289 (13)
 MTX+CsA +/− other 252 (31) 3589 (35)
 CsA +/− other 206 (25) 1799 (18)
Conditioning regimen <0.001
 Myeloablative 506 (61) 7276 (71)
 Non-myeloablative/RIC 319 (39) 2971 (29)
Lymphocyte depleting agents (ATG/alemtuzumab as conditioning or GVHD 
prophylaxis)
0.034
 ATG alone 270 (33) 2920 (28)
 Alemtuzumab alone 31 (4) 437 (4)
 No ATG or Alemtuzumab 524 (64) 6890 (67)
G-CSF, GM-CSF 0.512
 No 466 (56) 5667 (55)
 Yes 359 (44) 4580 (45)
Steroid containing GVHD prophylaxis 0.703
 No 790 (96) 9840 (96)
 Yes 35 (4) 407 (4)
Graft type 0.005
 Bone Marrow 193 (23) 2752 (27)
 Peripheral blood 508 (62) 6299 (61)
 Cord blood 124 (15) 1196 (12)
Year of transplant <0.001
 2001–2002 146 (18) 1969 (19)
 2003–2004 123 (15) 1972 (19)
 2005–2006 174 (21) 2571 (25)
 2007–2008 236 (29) 2546 (25)
 2009 146 (18) 1189 (12)
Median follow-up of survivors, months 37 (2 – 120) 48 (1 – 128)
Abbreviations: AML = acute myelogenous leukemia; ALL = acute lymphoblastic leukemia; CML = chronic myelogenous leukemia; GVHD = graft 
versus host disease; MTX = methotrexate; CsA = cyclosporine; FK506 = tacrolimus; BM = bone marrow; PB = peripheral blood; CB = cord blood; 
TBI = total body irradiation.
aOther mould infections included: Fusarium species and Cryptococcus species
bOther infections included: Histoplasmosis and other fungus
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Table 4
Cause of death of patients who underwent allogeneic transplants for AML, ALL, CML, MDS and had IFI 
within 12 months prior to HSCT vs. those who had no documented IFI within 12 months prior to HSCT, 
reported to the CIBMTR, from 2001 to 2009
Variable
Pre-tx invasive fungal infection
N(%)
All others
N(%)
Cause of death
 Graft rejection 2 (<1) 63 (1)
 Infection 107 (21) 919 (18)
 IPN 7 (1) 93 (2)
 Organ Failure 76 (15) 733 (14)
 GVHD 46 (9) 585 (11)
 Recurrent/Persistent Disease 242 (47) 2173 (42)
 Secondary malignancy 6 (1) 52 (1)
 Hemorrhage 13 (3) 131 (3)
 other cause 15 (3) 288 (6)
 Unknown 5 (<1) 77 (2)
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